4Moving Biotech welcomes Luc Boblet as Chief Executive Officer to lead next phase of growth

LILLE & PARIS, France–(BUSINESS WIRE)–4Moving Biotech (4MB), a clinical-stage subsidiary of 4P-Pharma specializing in immuno-inflammation and osteoarthritis, is pleased to announce the appointment of Luc Boblet as Chief Executive Officer. The company, having successfully completed its Phase I clinical trial and a preparatory in silico Phase 2 analysis, looks to Luc Boblet’s seasoned expertise in biotech entrepreneurship and strategic development to guide the forthcoming stages of clinical proof of concept and early market access.

Luc Boblet, a biotech entrepreneur with two decades of experience, joins 4MB following his tenure at Egle Therapeutics, where his leadership was essential in advancing novel immunotherapies and securing a robust Series A funding backed by a big pharma strategic alliance. His previous roles included founding and leading companies such as H-IMMUNE – acquired by HiFiBIO – and Pathoquest, where he excelled in driving innovation, closing fundraising and forging strategic partnerships as instrumental catalyst of growth.

Luc’s appointment comes at a turning point for 4Moving Biotech as we have concluded a milestone Phase I trial for our leading drug candidate and are advancing strategic discussions with the FDA, toward potential accelerated approval” said Revital Rattenbach, founder and CEO of 4P-Pharma and co-founder of 4Moving. His track record in steering biotech ventures and his strategic approach to partnerships will be invaluable as we advance our clinical programs and explore opportunities for pharma co-development and partnership.”

As CEO of 4Moving Biotech, Luc Boblet’s immediate focus will be on overseeing the design and implementation of the development strategy for the upcoming Phase II clinical trials, as well as cultivating partnerships that align with the company’s vision for growth and patient access to innovative treatments.

Luc Boblet, CEO of 4Moving Biotech said: “The opportunity to lead 4Moving Biotech at this juncture is one that is aligned with my commitment to bringing pioneering therapies for untreated severe diseases. The company’s progress in drug development and the potential to significantly improve patient outcomes in osteoarthritis is a strong foundation for future success. I am looking forward to applying my experience in corporate strategy business development to deliver our value proposal and establish meaningful partnerships.”

About 4Moving Biotech

4Moving Biotech, a subsidiary of 4P-Pharma, is dedicated to developing advanced first in class therapies in the field of immuno-inflammation and osteoarthritis. With a commitment to improving patient care, 4MB is actively engaged in the clinical development of novel treatments poised to enhance quality of life for patients worldwide.

Biography of Luc Boblet, CEO of 4Moving Biotech.

Luc Boblet is a serial biotech entrepreneur with 20 years of experience in entrepreneurship, business development, corporate finance and early drug development. Luc is coming from Egle Therapeutics, spin out of Institut Curie dedicated to developing novel Regulatory T-cells based immunotherapies for oncology and autoimmune diseases, he has co-founded in early 2020. As a founding CEO, he built Egle Tx with a vision to become a game changer in the field of Tregs immunomodulation catalyzed by strategic alliance with Takeda Pharmaceutical and backed by 45M€ Series A from a high-quality syndicate of renowned international investors. Before creating Egle Tx, Luc co-founded and ran H-IMMUNE, start-up spun out of French Nuclear Agency (CEA), developing novel anti-check-point immunotherapies against T-effector and Tregs for oncology. He paved H-IMMUNE corporate path through partnerships with Pierre Fabre Laboratories and Norther Biologics and have exited H-IMMUNE through an acquisition by HiFiBIO in 2018. Before co-founding H-IMMUNE, Luc co-founded and ran Pathoquest, a start-up company spun out of Institute Pasteur, which develops disruptive unbiased NGS-based diagnostics in the field of infectious diseases. Under his guidance, Pathoquest raised two VC-backed rounds of financing, closed strategic collaborations and corporate partnerships with leading pharma companies (CERBA Laboratories and Covance), and launched several clinicals trials in France and the U.S.

From 2011 to 2015, he served on the board of directors of the BioAster Technological Research Institute.

He started his career in technology transfer, consulting in finance and business development for toxicogenomics R&D. Luc Boblet holds a biotech engineering degree, master’s degree in Virology and has been trained as a PhD in Virology from University Paris VII.

About 4Moving Biotech

Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.

Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech

The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.


Emmanuel Dadje

Communication Manager – emmanuel.dadje@4P-Pharma.com
+33 6 30 06 12 13

Inmagene Reports Positive Interim Results from Phase 2a Trial of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Atopic Dermatitis

  • Treatment with IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis (AD).
  • Overall, IMG-007 was well-tolerated, without any reports of pyrexia or chills.
  • IMG-007 is also being evaluated for the treatment of alopecia areata (AA).
  • Final results are anticipated in Q3 2024.

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene” or the “Company”), a clinical-stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory (I&I) diseases, today announced positive interim data from Phase 2a trial of IMG-007 in patients with AD.


IMG-007 is a nondepleting anti-OX40 mAb, bioengineered to have a silenced antibody-dependent cellular cytotoxicity (ADCC) function and a prolonged half-life. In a prior Phase 1 single-dose study in healthy adults, IMG-007 demonstrated a favorable safety and tolerability profile, with no reports of pyrexia or chills, which is consistent with the abolished ADCC function. Furthermore, IMG-007 showed a slow antibody clearance and a 31-day half-life at anticipated therapeutic dose levels, which could enable it to be dosed every 12 weeks (Q12W) for induction therapy, and even less frequently for maintenance therapy in AD treatment.

The Phase 2a trial (NCT05984784) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Patients who had received prior systemic agents, such as biologics, were also included in the trial. Topical or systemic AD medications were not permitted during the study. Eligible patients were to receive three intravenous infusions of 300 mg IMG-007 over 4 weeks (Baseline, Week 2 and 4) and to be followed up for up to 24 weeks. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

A total of 13 patients were enrolled from 6 centers in the U.S. and Canada. Baseline key disease characteristics included mean EASI of 29.5, mean body surface area (BSA) of 52.0%, and 61.5% patients with investigator’s global assessment (IGA=3) and 38.5% with IGA=4.

IMG-007 treatment resulted in a rapid and marked improvement from baseline in EASI score as early as Week 1 and continued improvement over time after the last dose of IMG-007 at Week 4. The mean percent improvement from baseline in EASI was 23%, 29%, 47%, 66%, 68%,77%, and 87% at Weeks 1, 2, 4, 8, 12, 16, and 20, respectively.

By Week 20, a total of 69%, 54%, and 31% of patients achieved EASI improvement of at least 50% (EASI-50), at least 75% (EASI-75), and at least 90% (EASI-90), respectively.

There were no serious adverse events (SAEs), and no adverse events (AEs) leading to treatment discontinuation, and no treatment-related AEs. There were no reports of pyrexia or chills.

“Inhibiting OX40-OX40L signaling is an exciting potential therapeutic approach to treating AD,” said Jonathan Silverberg, M.D., Ph.D., Professor of Dermatology at The George Washington University School of Medicine and Health Sciences. “By uniquely targeting the OX40 receptor without depleting T cells and with its long half-life, IMG-007 presents a best-in-class potential to not only minimize safety risks associated with T cell depletion, but also provide patients with a more convenient dosing regimen such as Q12W.”

“We are highly encouraged by the remarkable efficacy seen with a short 4-week treatment period. Future studies of continuous treatment with IMG-007 in patients with AD could potentially drive more robust efficacy than seen in this proof-of-concept study,” said Yufang Lu, M.D., Ph.D., Chief Medical Officer of Inmagene. “Given the important role of the OX40-OX40L axis in the pathogenesis of a spectrum of I&I diseases, IMG-007 could be suitable for a number of indications. We are working hard to accelerate the clinical development of IMG-007 in AD with our subcutaneous formulation.”

In addition to the Phase 2a trial in patients with AD for which final results are anticipated in Q3 2024, IMG-007 is also being evaluated in a global study in adult patients with AA with anticipated initial data readout in Q4 2024.

About Inmagene

Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory (I&I) diseases. The company’s highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a nondepleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata (AA). IMG-004, a non-covalent reversible BTK inhibitor with an extended half-life and pharmacodynamic effect, enabling its potential for once-daily dosing, is completing a Phase 1 multiple-dose study. IMG-008, a long-acting anti-IL-36R mAb is entering global Phase 1 clinical development.

For more information, please visit www.inmagenebio.com.

About IMG-007

IMG-007 is a humanized anti-OX40 IgG1 mAb, with a silenced ADCC function and an extended half-life. The OX40-OX40L axis is important in T cell activation, expansion, and survival, thereby having an important role in the pathogenesis of a spectrum of I&I diseases. In nonclinical studies, IMG-007 potently blocked the signaling between OX40 and OX40L. Phase 1 single dose study demonstrated a 31-day half-life at anticipated therapeutic dose levels, enabling the potential for once every 12 weeks (Q12W) dosing for induction therapy and even less frequently for maintenance therapy, and a favorable safety profile, without any reports of pyrexia or chills. IMG-007 is being evaluated for the treatment of moderate-to-severe atopic dermatitis and alopecia areata in two Phase 2a studies.

Forward-Looking Statements

This press release contains forward-looking statements. While Inmagene believes the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

For further information, please contact:
Anna Vardanyan, MD, PhD
Vice President of Business Development

Investor Relations:
Bruce Mackle
LifeSci Advisors, LLC

Celon Pharma had the largest IPO on the Polish capital market in 2016

Celon Pharma

Continue reading